Atoltivimab (REGN3470) 与 maftivimab/odesivimab (Inmazeb)，是美国食品和药物管理局 (FDA) 批准的首个针对扎伊尔埃博拉病毒 (EBOV) 感染的单克隆抗体。
| 生物活性 | Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and Drug Administration (FDA)-approved monoclonal antibody to target Zaireebolavirus (EBOVs)infection[1]. |
| IC50& Target | |
| CAS 号 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com